Patrick B Broderick
Overview
Explore the profile of Patrick B Broderick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park H, Yin A, Barranta C, Lee J, Caputo C, Sachithanandham J, et al.
JCI Insight
. 2024 Mar;
9(8.
PMID: 38483534
BACKGROUNDCOVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined.METHODSThis secondary analysis correlated donor and recipient antibody levels...
2.
Huaman M, Raval J, Paxton J, Mosnaim G, Patel B, Anjan S, et al.
Transfusion
. 2023 Aug;
63(9):1639-1648.
PMID: 37534607
Background: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during...
3.
Park H, Yin A, Barranta C, Lee J, Caputo C, Sachithanandham J, et al.
medRxiv
. 2023 May;
PMID: 37131659
Background: The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient post-transfusion antibody levels sufficient to prevent disease progression is not defined. Methods: This secondary analysis correlated...
4.
Sullivan D, Gebo K, Shoham S, Bloch E, Lau B, Shenoy A, et al.
N Engl J Med
. 2022 Mar;
386(18):1700-1711.
PMID: 35353960
Background: Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset...
5.
How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
Bloch E, Tobian A, Shoham S, Hanley D, Gniadek T, Cachay E, et al.
Transfusion
. 2022 Mar;
62(5):933-941.
PMID: 35352362
Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable....
6.
Sullivan D, Gebo K, Shoham S, Bloch E, Lau B, Shenoy A, et al.
medRxiv
. 2022 Jan;
PMID: 34981068
Background: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain. Methods: This multicenter, double-blind randomized controlled...